Wordt geladen...
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for multiple metastatic cancers. However, its clinical use is limited by short half-life, low potency, and severe in vivo toxicity. Current IL-2 engineering strategies exhibit evidence of peripheral cytotoxicity. Her...
Bewaard in:
| Gepubliceerd in: | Nat Commun |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group UK
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8119481/ https://ncbi.nlm.nih.gov/pubmed/33986267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-22980-w |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|